Study of orelabrutinib for secondary progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have had relapsing-remitting MS (RRMS) in the past, and now have secondary progressive MS (SPMS).
- Your disability must have gotten worse over the last 2 years without any MS attacks (relapses).
- You must not have had any MS relapses in the last 2 years.
- You cannot have other serious medical conditions, certain infections, or be on blood thinners.
- You cannot have had a live vaccine in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This trial tests whether a pill called orelabrutinib can slow down ALS. It is an early-stage study to check safety and see if it may help people with ALS.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This trial tests a new drug called orelabrutinib given with standard chemotherapy for a specific subtype of diffuse large B-cell lymphoma (DLBCL) called MCD. The treatment aims to improve outcomes and is followed by a maintenance phase with orelabrutinib alone.
Hear when a new Secondary Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.